The ubiquitous BCR–ABL expression stimulates CML by activating CDK1 and cyclin B1, promoting pro-apoptotic, and inhibiting antiapoptotic marker expression along with regulations in RAS pathway activation. The gene discussed is CDK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.